OrphoMed Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $5.5M

  • Investors
  • 5

OrphoMed General Information

Description

Developer of a dimer therapeutics platform designed to treat Irritable bowel syndrome with diarrhea, opioid bowel dysfunction, and pain. The company's platform focuses on developing therapies for irritable bowel syndrome with diarrhea, acute and chronic pain, and cystic fibrosis, enabling patients to get first-line treatment for gastrointestinal disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • 50 Francisco Street
  • Suite 245
  • San Francisco, CA 94133
  • United States
+1 (415) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OrphoMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 28-Apr-2021 $5.5M 000.00 0000 Completed Clinical Trials - Phase 2
2. Debt - PPP 30-Apr-2020 00000 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 24-May-2017 $39M $39M 000.00 Completed Clinical Trials - Phase 2
To view OrphoMed’s complete valuation and funding history, request access »

OrphoMed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OrphoMed’s complete cap table history, request access »

OrphoMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a dimer therapeutics platform designed to treat Irritable bowel syndrome with diarrhea, opioid bowel dysfun
Biotechnology
San Francisco, CA
8 As of 2020
000.00
0000 0000-00-00
00000000000 000.00

000000

e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ull
0000 000000000
Tel Aviv, Israel
00 As of 0000
00000
000000000 00000

000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000 000000000
Copenhagen, Denmark
00 As of 0000
00000
00000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OrphoMed Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RedHill Biopharma Formerly VC-backed Tel Aviv, Israel 00 00000 000000000 00000
Galecto Formerly VC-backed Copenhagen, Denmark 00 00000 00000000 00000
Alcresta Therapeutics Private Equity-Backed Waltham, MA 00 000.00 000000000000 000.00
Union Therapeutics Venture Capital-Backed Hellerup, Denmark 00 00000 0000000000 0 00000
Cinclus Pharma Venture Capital-Backed Stockholm, Sweden 00 000.00 00000000 000.00
You’re viewing 5 of 24 competitors. Get the full list »

OrphoMed Patents

OrphoMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016344308-A1 Methods of treating pain or fever using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups Inactive 26-Oct-2015 0000000000
CA-3001851-A1 Methods of treating pain using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups Inactive 26-Oct-2015 0000000000
AU-2016344309-A1 Ethylene glycol ether of buprenorphine Inactive 26-Oct-2015 0000000000
EP-3368038-A1 Ethylene glycol ether of buprenorphine Inactive 26-Oct-2015 0000000000
CA-3002082-A1 Ethylene glycol ether of buprenorphine Inactive 26-Oct-2015 C07D498/02
To view OrphoMed’s complete patent history, request access »

OrphoMed Executive Team (12)

Name Title Board Seat
Frank Steinberg Co-Founder, Medical Advisor & Head of Medical Oversight
Pankaj Pasricha MD Co-Founder
Lisa Turner Vice President, Clinical & Medical
Kenneth Widder MD Executive Chairman
You’re viewing 4 of 12 executive team members. Get the full list »

OrphoMed Board Members (10)

Name Representing Role Since
Arthur Pappas Pappas Capital Board Member 000 0000
Blake Wu New Enterprise Associates Board Member 000 0000
Kenneth Widder MD Self Executive Chairman 000 0000
Michael Chao MD Relativity Healthcare Partners Board Member 000 0000
Michael Martin Ph.D Takeda Ventures Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

OrphoMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OrphoMed Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mario Family Fund Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Pappas Capital Venture Capital Minority 000 0000 000000 0
Relativity Healthcare Partners Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view OrphoMed’s complete investors history, request access »

OrphoMed FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »